These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19776413)

  • 1. The delayed-start study design.
    D'Agostino RB
    N Engl J Med; 2009 Sep; 361(13):1304-6. PubMed ID: 19776413
    [No Abstract]   [Full Text] [Related]  

  • 2. The delayed-start study in Parkinson disease: can't satisfy everyone.
    Olanow CW; Rascol O
    Neurology; 2010 Apr; 74(14):1149-50. PubMed ID: 20368635
    [No Abstract]   [Full Text] [Related]  

  • 3. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed start, rapid solution?
    Korczyn AD; Vakhapova V
    Neuroepidemiology; 2010; 35(3):214. PubMed ID: 20664295
    [No Abstract]   [Full Text] [Related]  

  • 5. What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?
    Vanacore N
    Neuroepidemiology; 2010; 35(3):213. PubMed ID: 20664294
    [No Abstract]   [Full Text] [Related]  

  • 6. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reexamination of the TEMPO Study.
    Shults CW
    Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
    Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
    Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Montgomery EB
    Neurology; 2010 Nov; 75(21):1943; author reply 1944-5. PubMed ID: 21155188
    [No Abstract]   [Full Text] [Related]  

  • 12. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Schwarzschild MA
    Neurology; 2010 Nov; 75(21):1943-4; author reply 1944-5. PubMed ID: 21098412
    [No Abstract]   [Full Text] [Related]  

  • 13. [The early therapy challenge].
    Reichmann H
    Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310
    [No Abstract]   [Full Text] [Related]  

  • 14. Designing and funding clinical trials of novel therapies.
    Antman K; Lagakos S; Drazen J
    N Engl J Med; 2001 Mar; 344(10):762-3. PubMed ID: 11236782
    [No Abstract]   [Full Text] [Related]  

  • 15. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of clinical wisdom in randomised studies, real-world registries and new hypotheses.
    Bernardi G; Morocutti G; Spedicato L; Zanuttini D
    J Cardiovasc Med (Hagerstown); 2007 May; 8(5):313-7. PubMed ID: 17443094
    [No Abstract]   [Full Text] [Related]  

  • 17. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S149-57; discussion S157-9. PubMed ID: 12666106
    [No Abstract]   [Full Text] [Related]  

  • 18. Neuroprotective trials: no longer a cautious optimism.
    Friedman JH
    Med Health R I; 2008 Jun; 91(6):158. PubMed ID: 18610798
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
    Hälbig TD; Tse W; Olanow CW
    Neurol Clin; 2004 Oct; 22(3 Suppl):S1-S17. PubMed ID: 15501359
    [No Abstract]   [Full Text] [Related]  

  • 20. Dihydroergocryptine in the treatment of Parkinson's disease.
    Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A
    J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.